Bellicum Pharmaceuticals (NASDAQ:BLCM) and Avedro (NASDAQ:AVDR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Institutional and Insider Ownership
59.1% of Bellicum Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.4% of Avedro shares are owned by institutional investors. 2.6% of Bellicum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Bellicum Pharmaceuticals and Avedro, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bellicum Pharmaceuticals presently has a consensus price target of $18.50, suggesting a potential upside of 1,467.80%. Avedro has a consensus price target of $19.40, suggesting a potential upside of 11.43%. Given Bellicum Pharmaceuticals’ higher possible upside, equities analysts plainly believe Bellicum Pharmaceuticals is more favorable than Avedro.
Earnings and Valuation
This table compares Bellicum Pharmaceuticals and Avedro’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bellicum Pharmaceuticals||$1.12 million||48.73||-$98.04 million||($2.44)||-0.48|
|Avedro||$27.67 million||10.74||-$25.12 million||($17.97)||-0.97|
Avedro has higher revenue and earnings than Bellicum Pharmaceuticals. Avedro is trading at a lower price-to-earnings ratio than Bellicum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Bellicum Pharmaceuticals and Avedro’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Avedro beats Bellicum Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products through a direct sales force in the United States and through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.